SELLAS Life Sciences Group Ownership 2024 | Who Owns SELLAS Life Sciences Group Now?
Institutional Ownership
7.26%
Insider Ownership
0.27%
Retail Ownership
92.47%
Institutional Holders
17.00
SELLAS Life Sciences Group Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ANSON FUNDS MANAGEMENT LP | 15.04% | 0.32% | 4,832,368 | 4,832,368 | 100.00% | 4,880,692 | Mar 31, 2024 |
| VANGUARD GROUP INC | 4.71% | - | 1,513,235 | 365,911 | 31.89% | 1,528,367 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4.27% | 0.00% | 1,372,700 | 1,372,700 | 100.00% | 1,386,427 | Mar 31, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 3.11% | 0.01% | 1,000,000 | -275,000 | -21.57% | 1,010,000 | Mar 31, 2024 |
| BLACKROCK INC. | 0.87% | - | 278,218 | -1,586 | -0.57% | 281,000 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.85% | - | 273,063 | 27,460 | 11.18% | 275,867 | Mar 31, 2024 |
| OPUS CAPITAL GROUP, LLC | 0.62% | 0.03% | 200,600 | 65,600 | 48.59% | 203,000 | Mar 31, 2024 |
| EQUITABLE HOLDINGS, INC. | 0.62% | 0.00% | 200,000 | 35,000 | 21.21% | 202,000 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.46% | - | 147,400 | -118,600 | -44.59% | 148,874 | Mar 31, 2024 |
| STATE STREET CORP | 0.30% | - | 97,129 | - | - | 98,100 | Mar 31, 2024 |
| NORTHERN TRUST CORP | 0.28% | - | 88,730 | 26,293 | 42.11% | 89,618 | Mar 31, 2024 |
| PROSPERITY FINANCIAL GROUP, INC. | 0.08% | 0.02% | 25,385 | 25,385 | 100.00% | 25,639 | Mar 31, 2024 |
| MARINER, LLC | 0.08% | 0.00% | 25,257 | 25,257 | 100.00% | 25,510,000 | Mar 31, 2024 |
| CANTOR FITZGERALD, L. P. | 0.08% | 0.01% | 24,750 | 24,750 | 100.00% | 24,998 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.07% | - | 23,100 | 23,100 | 100.00% | 23,331 | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.06% | 0.00% | 20,725 | 15,371 | 287.09% | 20,932 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.06% | - | 19,718 | 19,718 | 100.00% | 19,915 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.05% | 0.00% | 17,391 | -25,179 | -59.15% | 17,565 | Mar 31, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.05% | - | 16,238 | - | - | 16,400 | Mar 31, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.04% | - | 14,054 | 14,054 | 100.00% | 14,000 | Mar 31, 2024 |
SELLAS Life Sciences Group's largest institutional shareholder is ANSON FUNDS MANAGEMENT LP, holding 15.04% of the company's total share outstanding, currently valued at $4.88M. The top 10 institutional shareholders own together 30.86% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ANSON FUNDS MANAGEMENT LP | 15.04% | 0.32% | 4,832,368 | 4,832,368 | 100.00% | 4,880,692 | Mar 31, 2024 |
| OPUS CAPITAL GROUP, LLC | 0.62% | 0.03% | 200,600 | 65,600 | 48.59% | 203,000 | Mar 31, 2024 |
| PROSPERITY FINANCIAL GROUP, INC. | 0.08% | 0.02% | 25,385 | 25,385 | 100.00% | 25,639 | Mar 31, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 3.11% | 0.01% | 1,000,000 | -275,000 | -21.57% | 1,010,000 | Mar 31, 2024 |
| CANTOR FITZGERALD, L. P. | 0.08% | 0.01% | 24,750 | 24,750 | 100.00% | 24,998 | Mar 31, 2024 |
| BROOKLYN FI, LLC | 0.03% | 0.00% | 11,178 | 11,178 | 100.00% | 11,290 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.05% | 0.00% | 17,391 | -25,179 | -59.15% | 17,565 | Mar 31, 2024 |
| EQUITABLE HOLDINGS, INC. | 0.62% | 0.00% | 200,000 | 35,000 | 21.21% | 202,000 | Mar 31, 2024 |
| NEMES RUSH GROUP LLC | 0.03% | 0.00% | 10,000 | - | - | 10,100 | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.06% | 0.00% | 20,725 | 15,371 | 287.09% | 20,932 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4.27% | 0.00% | 1,372,700 | 1,372,700 | 100.00% | 1,386,427 | Mar 31, 2024 |
| MARINER, LLC | 0.08% | 0.00% | 25,257 | 25,257 | 100.00% | 25,510,000 | Mar 31, 2024 |
| VANGUARD GROUP INC | 4.71% | - | 1,513,235 | 365,911 | 31.89% | 1,528,367 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.46% | - | 147,400 | -118,600 | -44.59% | 148,874 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.85% | - | 273,063 | 27,460 | 11.18% | 275,867 | Mar 31, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.04% | - | 14,054 | 14,054 | 100.00% | 14,000 | Mar 31, 2024 |
| NORTHERN TRUST CORP | 0.28% | - | 88,730 | 26,293 | 42.11% | 89,618 | Mar 31, 2024 |
| BLACKROCK INC. | 0.87% | - | 278,218 | -1,586 | -0.57% | 281,000 | Mar 31, 2024 |
| STATE STREET CORP | 0.30% | - | 97,129 | - | - | 98,100 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.07% | - | 23,100 | 23,100 | 100.00% | 23,331 | Mar 31, 2024 |
The largest SELLAS Life Sciences Group shareholder by % of total assets is ANSON FUNDS MANAGEMENT LP. The company owns 4.83M shares of SELLAS Life Sciences Group (SLS), representing 0.32% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ANSON FUNDS MANAGEMENT LP | 15.04% | 0.32% | 4,832,368 | 4,832,368 | 100.00% | 4,880,692 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4.27% | 0.00% | 1,372,700 | 1,372,700 | 100.00% | 1,386,427 | Mar 31, 2024 |
| VANGUARD GROUP INC | 4.71% | - | 1,513,235 | 365,911 | 31.89% | 1,528,367 | Mar 31, 2024 |
| OPUS CAPITAL GROUP, LLC | 0.62% | 0.03% | 200,600 | 65,600 | 48.59% | 203,000 | Mar 31, 2024 |
| EQUITABLE HOLDINGS, INC. | 0.62% | 0.00% | 200,000 | 35,000 | 21.21% | 202,000 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.85% | - | 273,063 | 27,460 | 11.18% | 275,867 | Mar 31, 2024 |
| NORTHERN TRUST CORP | 0.28% | - | 88,730 | 26,293 | 42.11% | 89,618 | Mar 31, 2024 |
| PROSPERITY FINANCIAL GROUP, INC. | 0.08% | 0.02% | 25,385 | 25,385 | 100.00% | 25,639 | Mar 31, 2024 |
| MARINER, LLC | 0.08% | 0.00% | 25,257 | 25,257 | 100.00% | 25,510,000 | Mar 31, 2024 |
| CANTOR FITZGERALD, L. P. | 0.08% | 0.01% | 24,750 | 24,750 | 100.00% | 24,998 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.07% | - | 23,100 | 23,100 | 100.00% | 23,331 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.06% | - | 19,718 | 19,718 | 100.00% | 19,915 | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.06% | 0.00% | 20,725 | 15,371 | 287.09% | 20,932 | Mar 31, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.04% | - | 14,054 | 14,054 | 100.00% | 14,000 | Mar 31, 2024 |
| BROOKLYN FI, LLC | 0.03% | 0.00% | 11,178 | 11,178 | 100.00% | 11,290 | Mar 31, 2024 |
| FMR LLC | - | - | 1 | 1 | 100.00% | 1 | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | 2 | - | - | 2 | Mar 31, 2024 |
| MORGAN STANLEY | 0.00% | - | 1,420 | - | - | 1,434 | Mar 31, 2024 |
| PARKSIDE FINANCIAL BANK & TRUST | - | - | 2 | - | - | 3,000 | Mar 31, 2024 |
| ALLWORTH FINANCIAL LP | 0.00% | - | 150 | - | - | 152,000 | Mar 31, 2024 |
As of Mar 31 2024, SELLAS Life Sciences Group's largest institutional buyer is ANSON FUNDS MANAGEMENT LP. The company purchased 4.83M stocks of SLS, valued at $4.88M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | - | - | - | -820,000 | -100.00% | - | Mar 31, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 3.11% | 0.01% | 1,000,000 | -275,000 | -21.57% | 1,010,000 | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -186,355 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.46% | - | 147,400 | -118,600 | -44.59% | 148,874 | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -84,665 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -50,400 | -100.00% | - | Mar 31, 2024 |
| XTX TOPCO LTD | 0.05% | 0.00% | 17,391 | -25,179 | -59.15% | 17,565 | Mar 31, 2024 |
| ENGINEERS GATE MANAGER LP | - | - | - | -16,857 | -100.00% | - | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | 0.00% | - | 301 | -16,056 | -98.16% | 304,000 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -15,304 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.01% | - | 1,600 | -13,700 | -89.54% | 1,616 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -11,239 | -100.00% | - | Mar 31, 2024 |
| JPMORGAN CHASE & CO | 0.02% | - | 6,092 | -3,701 | -37.79% | 6,153 | Mar 31, 2024 |
| BLACKROCK INC. | 0.87% | - | 278,218 | -1,586 | -0.57% | 281,000 | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -42 | -100.00% | - | Mar 31, 2024 |
| NEMES RUSH GROUP LLC | 0.03% | 0.00% | 10,000 | - | - | 10,100 | Mar 31, 2024 |
| STATE STREET CORP | 0.30% | - | 97,129 | - | - | 98,100 | Mar 31, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.05% | - | 16,238 | - | - | 16,400 | Mar 31, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.01% | - | 1,660 | - | - | 1,676,000 | Mar 31, 2024 |
| JANICZEK WEALTH MANAGEMENT, LLC | - | - | 11 | - | - | 12,000 | Mar 31, 2024 |
As of Mar 31 2024, SELLAS Life Sciences Group's biggest institutional seller is ARMISTICE CAPITAL, LLC. The company sold -0.82M shares of SLS, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ANSON FUNDS MANAGEMENT LP | 15.04% | 0.32% | 4,832,368 | 4,832,368 | 100.00% | 4,880,692 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4.27% | 0.00% | 1,372,700 | 1,372,700 | 100.00% | 1,386,427 | Mar 31, 2024 |
| MARINER, LLC | 0.08% | 0.00% | 25,257 | 25,257 | 100.00% | 25,510,000 | Mar 31, 2024 |
| CANTOR FITZGERALD, L. P. | 0.08% | 0.01% | 24,750 | 24,750 | 100.00% | 24,998 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.07% | - | 23,100 | 23,100 | 100.00% | 23,331 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.06% | - | 19,718 | 19,718 | 100.00% | 19,915 | Mar 31, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.04% | - | 14,054 | 14,054 | 100.00% | 14,000 | Mar 31, 2024 |
| BROOKLYN FI, LLC | 0.03% | 0.00% | 11,178 | 11,178 | 100.00% | 11,290 | Mar 31, 2024 |
| FMR LLC | - | - | 1 | 1 | 100.00% | 1 | Mar 31, 2024 |
SELLAS Life Sciences Group's largest new institutional shareholder by number of shares is ANSON FUNDS MANAGEMENT LP, purchased 4.83M shares, valued at $4.88M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | - | - | - | -820,000 | -100.00% | - | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | - | - | - | -186,355 | -100.00% | - | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -84,665 | -100.00% | - | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -50,400 | -100.00% | - | Mar 31, 2024 |
| ENGINEERS GATE MANAGER LP | - | - | - | -16,857 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | - | - | - | -15,304 | -100.00% | - | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -11,239 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | - | - | - | -42 | -100.00% | - | Mar 31, 2024 |
SELLAS Life Sciences Group's largest sold out institutional shareholder by shares sold is ARMISTICE CAPITAL, LLC, sold -0.82M shares, valued at -, as of undefined.
SELLAS Life Sciences Group Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 0.03% | 14,905 | - | - | Dec 31, 2023 |
| FIDELITY COMMONWEALTH TRUST | 0.01% | 42,916 | - | - | Feb 29, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 1,490,000 | - | - | Feb 29, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,453,803 | 453,093 | 45.28% | Dec 31, 2023 |
| NORTHERN FUNDS | 0.00% | 2,500,000 | - | - | Dec 29, 2023 |
| NORTHERN FUNDS | 0.00% | 2,500,000 | - | - | Dec 29, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 245,865 | 12,947 | 5.56% | Feb 29, 2024 |
| NORTHERN FUNDS | 0.00% | 1,000,000 | - | - | Dec 29, 2023 |
| NORTHERN FUNDS | 0.00% | 1,000,000 | - | - | Dec 29, 2023 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 17,100 | - | - | Feb 29, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 195,000 | - | - | Feb 29, 2024 |
| NORTHERN FUNDS | 0.00% | 500,000 | - | - | Dec 29, 2023 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 14,948 | - | - | Dec 31, 2023 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 55,000 | - | - | Feb 29, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 50,000 | - | - | Feb 29, 2024 |
| RBB FUND, INC. | 0.00% | 11,400 | - | - | Feb 29, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 10,000 | - | - | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 26,905 | - | - | Jan 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 5,252 | - | - | Dec 31, 2023 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 4,399 | - | - | Jan 31, 2024 |
| iSHARES TRUST | 0.00% | 61,814 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 418 | - | - | Dec 31, 2023 |
| Morningstar Funds Trust | 0.00% | 245,000 | - | - | Jan 31, 2024 |
SELLAS Life Sciences Group's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 14.90K shares, compromising 0.03% of its total assets.
SELLAS Life Sciences Group Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 17 | -45.16% |
| 31 Dec, 23 | 31 | 14.81% |
| 30 Sep, 23 | 27 | 12.50% |
| 30 Jun, 23 | 24 | -4.00% |
| 31 Mar, 23 | 25 | -13.79% |
| 31 Dec, 22 | 29 | - |
| 30 Sep, 22 | 29 | 7.41% |
| 30 Jun, 22 | 27 | -3.57% |
| 31 Mar, 22 | 28 | 7.69% |
| 31 Dec, 21 | 26 | -13.33% |
| 30 Sep, 21 | 30 | -14.29% |
| 30 Jun, 21 | 35 | 6.06% |
| 31 Mar, 21 | 33 | 83.33% |
| 31 Dec, 20 | 18 | 80.00% |
| 30 Sep, 20 | 10 | -9.09% |
| 30 Jun, 20 | 11 | 10.00% |
| 31 Mar, 20 | 10 | -9.09% |
| 31 Dec, 19 | 11 | 1000.00% |
| 30 Sep, 19 | 1 | - |
| 30 Jun, 19 | 1 | - |
| 31 Mar, 19 | 1 | - |
As of 31 Mar 24, 17 institutions are holding SELLAS Life Sciences Group's shares, representing a decrease of -45.16% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 2,332,194 | -33.00% |
| 31 Dec, 23 | 3,480,630 | 30.42% |
| 30 Sep, 23 | 2,668,818 | -13.53% |
| 30 Jun, 23 | 3,086,263 | -35.72% |
| 31 Mar, 23 | 4,801,182 | 154.13% |
| 31 Dec, 22 | 1,889,269 | -13.62% |
| 30 Sep, 22 | 2,187,085 | -26.60% |
| 30 Jun, 22 | 2,979,650 | 88.96% |
| 31 Mar, 22 | 1,576,898 | -2.56% |
| 31 Dec, 21 | 1,618,287 | -5.82% |
| 30 Sep, 21 | 1,718,242 | 3.56% |
| 30 Jun, 21 | 1,659,116 | 19.72% |
| 31 Mar, 21 | 1,385,850 | 49.81% |
| 31 Dec, 20 | 925,077 | 50.01% |
| 30 Sep, 20 | 616,676 | 38.54% |
| 30 Jun, 20 | 445,128 | 7.03% |
| 31 Mar, 20 | 415,895 | 6.62% |
| 31 Dec, 19 | 390,067 | 13002133.33% |
| 30 Sep, 19 | 3 | - |
| 30 Jun, 19 | 3 | - |
| 31 Mar, 19 | 3 | - |
SELLAS Life Sciences Group (SLS) has 2.33M shares outstanding as of 31 Mar 24, down -33.00% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 7.26% | 4.82% |
| 31 Dec, 23 | 12.28% | 13.85% |
| 30 Sep, 23 | 9.41% | 5.48% |
| 30 Jun, 23 | 13.11% | 3.15% |
| 31 Mar, 23 | 20.39% | 21.49% |
| 31 Dec, 22 | 9.74% | 8.61% |
| 30 Sep, 22 | 10.64% | 4.93% |
| 30 Jun, 22 | 14.69% | 14.93% |
| 31 Mar, 22 | 9.92% | 9.54% |
| 31 Dec, 21 | 10.19% | 8.70% |
| 30 Sep, 21 | 10.82% | 9.17% |
| 30 Jun, 21 | 10.87% | 12.52% |
| 31 Mar, 21 | 9.32% | 7.71% |
| 31 Dec, 20 | 10.99% | 20.48% |
| 30 Sep, 20 | 7.33% | 16.69% |
| 30 Jun, 20 | 6.63% | 15.57% |
| 31 Mar, 20 | 6.52% | 17.43% |
| 31 Dec, 19 | 6.12% | 87331547000.00% |
| 30 Sep, 19 | 0.00% | 1000000.00% |
| 30 Jun, 19 | 0.00% | 1000000.00% |
| 31 Mar, 19 | 0.00% | - |
As of 31 Mar 24, SELLAS Life Sciences Group is held by 7.26% institutional shareholders, representing a 4.82% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 7 | -63.16% |
| 31 Dec, 23 | 19 | 46.15% |
| 30 Sep, 23 | 13 | 18.18% |
| 30 Jun, 23 | 11 | -8.33% |
| 31 Mar, 23 | 12 | -40.00% |
| 31 Dec, 22 | 20 | 122.22% |
| 30 Sep, 22 | 9 | -43.75% |
| 30 Jun, 22 | 16 | 33.33% |
| 31 Mar, 22 | 12 | 9.09% |
| 31 Dec, 21 | 11 | -31.25% |
| 30 Sep, 21 | 16 | -20.00% |
| 30 Jun, 21 | 20 | - |
| 31 Mar, 21 | 20 | 53.85% |
| 31 Dec, 20 | 13 | 160.00% |
| 30 Sep, 20 | 5 | - |
| 30 Jun, 20 | 5 | -28.57% |
| 31 Mar, 20 | 7 | -36.36% |
| 31 Dec, 19 | 11 | - |
| 30 Sep, 19 | - | - |
| 30 Jun, 19 | - | -100.00% |
| 31 Mar, 19 | 1 | - |
7 institutional shareholders have increased their position in SLS stock as of 31 Mar 24 compared to 19 in the previous quarter (a -63.16% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 4 | -20.00% |
| 31 Dec, 23 | 5 | - |
| 30 Sep, 23 | 5 | 66.67% |
| 30 Jun, 23 | 3 | - |
| 31 Mar, 23 | 3 | - |
| 31 Dec, 22 | 3 | -66.67% |
| 30 Sep, 22 | 9 | 125.00% |
| 30 Jun, 22 | 4 | -42.86% |
| 31 Mar, 22 | 7 | 16.67% |
| 31 Dec, 21 | 6 | - |
| 30 Sep, 21 | 6 | 50.00% |
| 30 Jun, 21 | 4 | - |
| 31 Mar, 21 | 4 | 100.00% |
| 31 Dec, 20 | 2 | -33.33% |
| 30 Sep, 20 | 3 | 50.00% |
| 30 Jun, 20 | 2 | 100.00% |
| 31 Mar, 20 | 1 | - |
| 31 Dec, 19 | - | - |
| 30 Sep, 19 | - | - |
| 30 Jun, 19 | - | - |
| 31 Mar, 19 | - | - |
4 institutional shareholders have reduced their position in SLS stock as of 31 Mar 24 compared to 5 in the previous quarter (a -20.00% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 17 | -45.16% | 2,332,194 | -33.00% | 7.26% | 4.82% | 7 | -63.16% | 4 | -20.00% |
| 31 Dec, 23 | 31 | 14.81% | 3,480,630 | 30.42% | 12.28% | 13.85% | 19 | 46.15% | 5 | - |
| 30 Sep, 23 | 27 | 12.50% | 2,668,818 | -13.53% | 9.41% | 5.48% | 13 | 18.18% | 5 | 66.67% |
| 30 Jun, 23 | 24 | -4.00% | 3,086,263 | -35.72% | 13.11% | 3.15% | 11 | -8.33% | 3 | - |
| 31 Mar, 23 | 25 | -13.79% | 4,801,182 | 154.13% | 20.39% | 21.49% | 12 | -40.00% | 3 | - |
| 31 Dec, 22 | 29 | - | 1,889,269 | -13.62% | 9.74% | 8.61% | 20 | 122.22% | 3 | -66.67% |
| 30 Sep, 22 | 29 | 7.41% | 2,187,085 | -26.60% | 10.64% | 4.93% | 9 | -43.75% | 9 | 125.00% |
| 30 Jun, 22 | 27 | -3.57% | 2,979,650 | 88.96% | 14.69% | 14.93% | 16 | 33.33% | 4 | -42.86% |
| 31 Mar, 22 | 28 | 7.69% | 1,576,898 | -2.56% | 9.92% | 9.54% | 12 | 9.09% | 7 | 16.67% |
| 31 Dec, 21 | 26 | -13.33% | 1,618,287 | -5.82% | 10.19% | 8.70% | 11 | -31.25% | 6 | - |
| 30 Sep, 21 | 30 | -14.29% | 1,718,242 | 3.56% | 10.82% | 9.17% | 16 | -20.00% | 6 | 50.00% |
| 30 Jun, 21 | 35 | 6.06% | 1,659,116 | 19.72% | 10.87% | 12.52% | 20 | - | 4 | - |
| 31 Mar, 21 | 33 | 83.33% | 1,385,850 | 49.81% | 9.32% | 7.71% | 20 | 53.85% | 4 | 100.00% |
| 31 Dec, 20 | 18 | 80.00% | 925,077 | 50.01% | 10.99% | 20.48% | 13 | 160.00% | 2 | -33.33% |
| 30 Sep, 20 | 10 | -9.09% | 616,676 | 38.54% | 7.33% | 16.69% | 5 | - | 3 | 50.00% |
| 30 Jun, 20 | 11 | 10.00% | 445,128 | 7.03% | 6.63% | 15.57% | 5 | -28.57% | 2 | 100.00% |
| 31 Mar, 20 | 10 | -9.09% | 415,895 | 6.62% | 6.52% | 17.43% | 7 | -36.36% | 1 | - |
| 31 Dec, 19 | 11 | 1000.00% | 390,067 | 13002133.33% | 6.12% | 87331547000.00% | 11 | - | - | - |
| 30 Sep, 19 | 1 | - | 3 | - | 0.00% | 1000000.00% | - | - | - | - |
| 30 Jun, 19 | 1 | - | 3 | - | 0.00% | 1000000.00% | - | -100.00% | - | - |
| 31 Mar, 19 | 1 | - | 3 | - | 0.00% | - | 1 | - | - | - |
SELLAS Life Sciences Group Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of SELLAS Life Sciences Group's stock was made by WOOD BARBARA A on Dec 08 2023, selling 4,119 shares at $1.08 per share (valued at $4.45K).
SELLAS Life Sciences Group Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q4 2023 | - | 4 | - |
| Q1 2023 | 18 | - | - |
| Q4 2022 | - | 3 | - |
| Q3 2022 | 1 | 1 | 100.00% |
| Q1 2022 | 15 | 1 | 1500.00% |
| Q4 2021 | - | 3 | - |
| Q1 2021 | 10 | - | - |
| Q1 2020 | 10 | - | - |
| Q1 2019 | 9 | - | - |
| Q4 2018 | - | 3 | - |
| Q3 2018 | - | 1 | - |
| Q2 2018 | 7 | 1 | 700.00% |
| Q1 2018 | 10 | 1 | 1000.00% |
| Q4 2017 | 17 | 8 | 212.50% |
| Q3 2017 | 7 | - | - |
| Q2 2017 | 13 | 1 | 1300.00% |
| Q1 2017 | 10 | 1 | 1000.00% |
| Q4 2016 | 1 | - | - |
| Q3 2016 | 10 | - | - |
| Q2 2016 | 1 | 1 | 100.00% |
0 total buy trades, and 4 total sell trades (buy/sell ratio of 0.00%) were made by SELLAS Life Sciences Group's insiders, as of Q4 2023.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q4 2023 | - | - | - |
| Q1 2023 | - | - | - |
| Q4 2022 | - | 3 | - |
| Q3 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | 3 | - |
| Q1 2021 | - | - | - |
| Q1 2020 | - | - | - |
| Q1 2019 | - | - | - |
| Q4 2018 | - | 1 | - |
| Q3 2018 | - | - | - |
| Q2 2018 | - | - | - |
| Q1 2018 | - | - | - |
| Q4 2017 | - | - | - |
| Q3 2017 | - | - | - |
| Q2 2017 | - | 1 | - |
| Q1 2017 | 1 | 1 | 100.00% |
| Q4 2016 | - | - | - |
| Q3 2016 | - | - | - |
| Q2 2016 | - | - | - |
As of Q4 2023, Insider owners conducted 0 open market buy trades and 0 open market sell trades of SELLAS Life Sciences Group's stocks.
SELLAS Life Sciences Group Peer Ownership
| Ticker | Company |
|---|---|
| EYEN | Eyenovia, Inc. |
| ZURA | Zura Bio Limited |
| MREO | Mereo BioPharma Group plc |
| SAVA | Cassava Sciences, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| NLSP | NLS Pharmaceutics AG |
| EYPT | EyePoint Pharmaceuticals, Inc. |
| ELEV | Elevation Oncology, Inc. |
| OCUP | Ocuphire Pharma, Inc. |
| IMMX | Immix Biopharma, Inc. |
| AXSM | Axsome Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| MCRB | Seres Therapeutics, Inc. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| KOD | Kodiak Sciences Inc. |
| ENVB | Enveric Biosciences, Inc. |
| CGTX | Cognition Therapeutics, Inc. |
| ANVS | Annovis Bio, Inc. |
SLS Ownership FAQ
Who Owns SELLAS Life Sciences Group?
SELLAS Life Sciences Group is owned by institutional shareholders (7.26%), insiders (0.27%), and public (92.47%). The largest institutional shareholder of SELLAS Life Sciences Group is ANSON FUNDS MANAGEMENT LP (15.04% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.03% of total shares).
Who are the major institutional shareholders of SELLAS Life Sciences Group?
SELLAS Life Sciences Group's major institutional shareholders are ANSON FUNDS MANAGEMENT LP, VANGUARD GROUP INC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, ALYESKA INVESTMENT GROUP, L.P., and BLACKROCK INC.. The top five shareholders own together 28.01% of the company's share outstanding.
How many SELLAS Life Sciences Group shareholders are there?
As of Mar 2024, there are 17 institutional shareholders of SELLAS Life Sciences Group.
What percentage of SELLAS Life Sciences Group is owned by ANSON FUNDS MANAGEMENT LP?
ANSON FUNDS MANAGEMENT LP owns 4.83M shares of SELLAS Life Sciences Group, representing 15.04% of the company's total shares outstanding, valued at $4.88M (as of Mar 2024).
What percentage of SELLAS Life Sciences Group is owned by VANGUARD GROUP INC?
As of Mar 2024, VANGUARD GROUP INC holds 1.51M shares of SELLAS Life Sciences Group (SLS), compromising 4.71% of the company, valued at $1.53M.
What percentage of SELLAS Life Sciences Group is owned by SUSQUEHANNA INTERNATIONAL GROUP, LLP?
SUSQUEHANNA INTERNATIONAL GROUP, LLP is the third largest holder of SELLAS Life Sciences Group. The company owns 1.37M of the company's shares outstanding (worth $1.39M).